3 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 4 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma trials Research Report on Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-05-20 | 2026-07-09 |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 120 | 2024-01-31 | 2024-09-26 |
| Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Recruiting | Lapo Alinari | 18 | 2023-03-06 | 2026-02-27 |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-10-22 |
Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Follicular (1) · Pyloric Stenosis, Hypertrophic (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, B-Cell (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Digestive System Diseases (1) · Gastric Outlet Obstruction (1) · Gastrointestinal Diseases (1) · Pyloric Stenosis (1) · Stomach Diseases (1)
Magnetic Resonance Spectroscopy (5) · Biopsy (4) · Specimen Handling (4) · Cyclophosphamide (2) · Spinal Puncture (2) · CT-P10 (1) · Doxorubicin (1) · Etoposide (1) · Lenalidomide (1) · NKTR-255 (1) · Observation (1) · Phantoms, Imaging (1) · Prednisone (1) · Rituximab (1) · Vincristine (1)
National Cancer Institute (NCI) (2) · Academic and Community Cancer Research United (1) · Fred Hutchinson Cancer Center (1) · Lapo Alinari (1) · Northside Hospital, Inc. (1)
United States (6)
Alexandre Hirayama (1) · Grzegorz S Nowakowski (1) · Jeremy S Abramson (1) · Joseph M Tuscano (1) · Lapo Alinari, MD, PhD (1)
P30CA015083 (1), U10CA180821 (1), UM1CA186717 (1)